ASCO® 2023 Insights: "TEDOVA Trial - Neo-Epitope Based Vaccine Alone or in Combination With Pembro vs. BSC as Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer With Disease Control After Platinum"

380 views
June 9, 2023
Comments 0
Login to view comments. Click here to Login